Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer

Arch Pathol Lab Med. 2015 Dec;139(12):1477-8. doi: 10.5858/arpa.2015-0902-ED.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • B7-H1 Antigen / analysis*
  • B7-H1 Antigen / antagonists & inhibitors
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / antagonists & inhibitors
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Nivolumab
  • Programmed Cell Death 1 Receptor / analysis*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab